Cyto Sorbents, Corp. (OTCBB:CTSO) Surges Ahead on Sales, Earnings Expectations
Cyto Sorbents, Corp. (OTCBB:CTSO) is spiking on record volumes, growing by more than 23% on Thursday, to 15 cents, as buying reached above $711,000. CTSO rises without the benefit of a promotion, though it still has not fulfilled its promise for uplisting. 
Still, CTSO is the rare OTC ticker that combines a robust growth with good underlying financials:
- $2.06 million cash assets
- $3.2 million current assets
- $2.07 million current liabilities
- $651,980 net loss
On January 7th, the stock price rose to a yearly high, and even without promoters, analysts on the Web have mentioned the company in an assertive enough manner to invite new investors. CTSO started its tentative climb in September, doubling its price since then, though the most eventful growth happened in the last month, when news around the company started to arrive more actively.
CTSO has the profile of a company that has had loyal investors, which are now in anticipation of a bigger development on the stock markets. Now, investors’ forums are starting a momentum of wild optimism for this ticker, which is priced just right for a dramatic run.
CTSO is producing technologies for filtering out blood for toxic substances, with a potential application in many medical avenues. While still not profitable, CTSO is showing an increase in revenues, and a new report could further entice investors to buy, or hold.
In addition, CTSO is starting to commercialize its CytoSorb® blood purification therapy, already approved in the European Union. Now, the company is in preparation of its 2013 financial report, which will be one of the big events, given that the past 12 months came in with the full commercialization of the company’s products. The last quarter was immensely successful, ramping up sales by 60% compared to Q3 in 2012, to $330,000.
CTSO is comparable, or better in the opportunity offered, to another recent mover, Natural Health Trends, Corp. (OTCMKTS:NHTC). The direct sales company boasts a long history and robust revenues, something of a rarity among OTC companies in the pharmaceutical sector.
Also, CTSO is differentiated from the medical cannabis hype, thus in no danger of rapidly wiping out its value. AVT, Inc. (OTCMKTS:AVTC) which also boasts a relatively developed business, was lifted disproportionately for just a tentative suggestion it is now a “pot stock”- and later suffered a rather painful setback.
In the case of CTSO, while waiting for the big event, estimate well your time frame, to avoid getting caught in periods of downward pressure.
